CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Arovella Therapeutics Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Arovella Therapeutics Ltd
Osborne Park, U 12 L 1, 55 Howe St
Phone: +61 861425555p:+61 861425555 PERTH, VIC  3053  Australia Ticker: ALAALA

Business Summary
Arovella Therapeutics Limited is an Australia-based biotechnology company. The Company is focused on developing therapies to treat human disease. The Company’s two focus areas are oncology and conditions that impact the central nervous system. The Company’s technology includes iNKT Cell Therapy, CAR19-iNKT + CF33-CD19, and CLDN18.2-iNKT. The Company’s invariant natural killer T (iNKT) cell therapy pipeline through the license to the DKK1 monoclonal antibody (mAb). It develops the DKK1 mAb as a chimeric antigen receptor, they focus on finding and destroying cancer cells. The Company’s invariant natural killer T (iNKT) cell therapy platform is a differentiated cancer therapeutic with the potential to treat various blood cancers and solid tumors.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/20236/30/2023Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Chairman of the Board ThomasDuthy 3/13/2023 3/13/2023
Chief Executive Officer, Managing Director, Director MichaelBaker 1/1/2022 1/2/2020
Chief Financial Officer, Company Secretary TimLuscombe 12/1/2023 12/1/2023
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
NovaDel Pharma, Inc. 1200 US Highway 22 Bridgewater NJ United States

Business Names
Business Name
ALA
Ampack Medical Pty Ltd
Eastland Medical Systems Ltd
5 additional Business Names available in full report.

General Information
Number of Employees: 14 (As of 6/30/2013)
Outstanding Shares: 909,628,062 (As of 12/31/2023)
Shareholders: 2,857
Stock Exchange: ASX
Fax Number: +61 894438858


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, March 18, 2024